MiNK Therapeutics Advances Phase 2 Programs

MiNK Therapeutics reported its fourth-quarter and full-year 2025 results, highlighting significant progress in its Phase 2 programs. The company anticipates initiating a Phase 2 trial for ARDS / hypoxemic pneumonia in the first half of 2026, with early data expected by year-end. This trial targets an annual market opportunity estimated between 200,000 to 300,000 patients. The advancement of these programs, coupled with non-dilutive funding momentum, positions MiNK Therapeutics for potential growth and market impact in its therapeutic areas.